Cisplatin resistance and opportunities for precision medicine

详细信息    查看全文

• 作者：Lauren Amable ; ^{lauren.amable@nih.gov" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ABC ; ATP-binding cassette ; ASE-1 ; anti-sense ERCC1 ; ATP7A ; ATPase copper-transporting alpha polypeptide ; ATP7B ; ATPase copper-transporting beta polypeptide ; CAST ; T-cell receptor complex subunit CD3ε-associated signal transducer ; CTR1 ; copper transporter 1 ; CTR2 ; copper transporter 2 ; ERCC1 ; excision repair cross-complementation group 1 gene ; GSH ; glutathione ; GST ; glutathione-s-transferase ; MRP ; multidrug resistance associated protein ; MT ; metallothionein ; NER ; nucleotide excision repair ; NSCLC
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：106
• 期：Complete
• 页码：27-36
• 全文大小：1712 K

文摘

Cisplatin is one of the most commonly used chemotherapy drugs, treating a wide range of cancer types. Unfortunately, many cancers initially respond to platinum treatment but when the tumor returns, drug resistance frequently occurs. Resistance to cisplatin is attributed to three molecular mechanisms: increased DNA repair, altered cellular accumulation, and increased drug inactivation. The use of precision medicine to make informed decisions on a patient’s cisplatin resistance status and predicting the tumor response would allow the clinician to tailor the chemotherapy program based on the biology of the disease. In this review, key biomarkers of each molecular mechanism will be discussed along with the current clinical research. Additionally, known polymorphisms for each biomarker will be discussed in relation to their influence on cisplatin resistance.